Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Abbott receives FDA clearance for it OCT imaging platform » 09:02
08/03/21
08/03
09:02
08/03/21
09:02
ABT

Abbott

$120.94 /

-0.06 (-0.05%)

Abbott announced it has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABT Abbott
$120.94 /

-0.06 (-0.05%)

ABT Abbott
$120.94 /

-0.06 (-0.05%)

07/30/21 SVB Leerink
DexCom price target raised to $500 from $485 at SVB Leerink
07/23/21 Raymond James
Abbott price target raised to $128 from $116 at Raymond James
07/12/21 Wells Fargo
Abbott price target raised to $135 from $125 at Wells Fargo
07/01/21 Piper Sandler
DexCom settlement with Abbott could be lucrative, says Piper Sandler
ABT Abbott
$120.94 /

-0.06 (-0.05%)

ABT Abbott
$120.94 /

-0.06 (-0.05%)

ABT Abbott
$120.94 /

-0.06 (-0.05%)

ABT Abbott
$120.94 /

-0.06 (-0.05%)

Hot Stocks
Genentech announces FDA acceptance of Tecentriq sBLA » 05:24
08/03/21
08/03
05:24
08/03/21
05:24
RHHBY

Roche

$48.54 /

+0.28 (+0.58%)

Genentech, a member of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RHHBY Roche
$48.54 /

+0.28 (+0.58%)

RHHBY Roche
$48.54 /

+0.28 (+0.58%)

08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
07/23/21 Barclays
Roche price target raised to CHF 395 from CHF 375 at Barclays
07/22/21 UBS
Roche price target raised to CHF 375 from CHF 330 at UBS
RHHBY Roche
$48.54 /

+0.28 (+0.58%)

RHHBY Roche
$48.54 /

+0.28 (+0.58%)

RHHBY Roche
$48.54 /

+0.28 (+0.58%)

Yesterday
Hot Stocks
Fate Therapeutics treats first patient in phase 1 clinical trial of FT819 » 16:52
08/02/21
08/02
16:52
08/02/21
16:52
FATE

Fate Therapeutics

$85.15 /

+2.37 (+2.86%)

Fate Therapeutics…

Fate Therapeutics "announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell line, a renewable cell source that enables mass production of high quality, allogeneic CAR T cells with greater product consistency, off-the-shelf availability, and broader patient accessibility. FT819 is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy. The multi-center Phase 1 clinical trial of FT819 is designed to determine the recommended Phase 2 dose and schedule of FT819 and assess its safety and clinical activity in adult patients with relapsed/refractory acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL), and B-cell lymphomas. Three treatment regimens will be independently evaluated for each type of malignancy in dose escalation: Regimen A as a single dose of FT819; Regimen B as a single dose of FT819 with IL-2 cytokine support; and Regimen C as three fractionated doses of FT819. For each indication and regimen, dose-expansion cohorts may be enrolled to further evaluate the clinical activity of FT819. The first patient with relapsed / refractory ALL was enrolled in Regimen A and received a dose of 90 million cells."

ShowHide Related Items >><<
FATE Fate Therapeutics
$85.15 /

+2.37 (+2.86%)

FATE Fate Therapeutics
$85.15 /

+2.37 (+2.86%)

07/13/21 Piper Sandler
Century Therapeutics initiated with an Overweight at Piper Sandler
06/11/21 BMO Capital
Fate Therapeutics coverage transferred at BMO Capital
06/07/21 H.C. Wainwright
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
06/04/21 Roth Capital
Fate Therapeutics duration response remains unknown, says Roth Capital
FATE Fate Therapeutics
$85.15 /

+2.37 (+2.86%)

  • 06
    Jan
FATE Fate Therapeutics
$85.15 /

+2.37 (+2.86%)

Conference/Events
SVB Leerink pharmaceuticals analysts hold analyst/industry conference call » 14:25
08/02/21
08/02
14:25
08/02/21
14:25
FATE

Fate Therapeutics

$85.71 /

+2.93 (+3.54%)

Pharmaceuticals Analysts…

Pharmaceuticals Analysts and Medacorp Specialists provide a preview of the upcoming readouts for Fate Therapeutics' off-the-shelf NK Cell Therapies in B-Cell Lymphomas on an Analyst/Industry conference call to be held on August 2 at 3 pm.

ShowHide Related Items >><<
FATE Fate Therapeutics
$85.71 /

+2.93 (+3.54%)

FATE Fate Therapeutics
$85.71 /

+2.93 (+3.54%)

07/13/21 Piper Sandler
Century Therapeutics initiated with an Overweight at Piper Sandler
06/11/21 BMO Capital
Fate Therapeutics coverage transferred at BMO Capital
06/07/21 H.C. Wainwright
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
06/04/21 Roth Capital
Fate Therapeutics duration response remains unknown, says Roth Capital
FATE Fate Therapeutics
$85.71 /

+2.93 (+3.54%)

  • 06
    Jan
FATE Fate Therapeutics
$85.71 /

+2.93 (+3.54%)

Recommendations
Roche price target raised to CHF 360 from CHF 310 at JPMorgan » 14:23
08/02/21
08/02
14:23
08/02/21
14:23
RHHBY

Roche

$48.26 /

+0.5 (+1.05%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser raised the firm's price target on Roche to CHF 360 from CHF 310 and keeps a Neutral rating on the shares.

ShowHide Related Items >><<
RHHBY Roche
$48.26 /

+0.5 (+1.05%)

RHHBY Roche
$48.26 /

+0.5 (+1.05%)

07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
07/23/21 Barclays
Roche price target raised to CHF 395 from CHF 375 at Barclays
07/22/21 UBS
Roche price target raised to CHF 375 from CHF 330 at UBS
07/19/21 UBS
Roche price target raised to CHF 345 from CHF 330 at UBS
RHHBY Roche
$48.26 /

+0.5 (+1.05%)

RHHBY Roche
$48.26 /

+0.5 (+1.05%)

RHHBY Roche
$48.26 /

+0.5 (+1.05%)

Conference/Events
SVB Leerink pharmaceuticals analysts hold analyst/industry conference call » 09:49
08/02/21
08/02
09:49
08/02/21
09:49
FATE

Fate Therapeutics

$83.66 /

+0.88 (+1.06%)

Pharmaceuticals Analysts…

Pharmaceuticals Analysts and Medacorp Specialists provide a preview of the upcoming readouts for Fate Therapeutics' off-the-shelf NK Cell Therapies in B-Cell Lymphomas on an Analyst/Industry conference call to be held on August 2 at 3 pm.

ShowHide Related Items >><<
FATE Fate Therapeutics
$83.66 /

+0.88 (+1.06%)

FATE Fate Therapeutics
$83.66 /

+0.88 (+1.06%)

07/13/21 Piper Sandler
Century Therapeutics initiated with an Overweight at Piper Sandler
06/11/21 BMO Capital
Fate Therapeutics coverage transferred at BMO Capital
06/07/21 H.C. Wainwright
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
06/04/21 Roth Capital
Fate Therapeutics duration response remains unknown, says Roth Capital
FATE Fate Therapeutics
$83.66 /

+0.88 (+1.06%)

  • 06
    Jan
FATE Fate Therapeutics
$83.66 /

+0.88 (+1.06%)

Hot Stocks
Abbott's FreeStyle Libre 2 iOS app cleared in U.S. » 09:03
08/02/21
08/02
09:03
08/02/21
09:03
ABT

Abbott

$121.00 /

-0.11 (-0.09%)

Abbott's FreeStyle…

Abbott's FreeStyle Libre 2 iOS application has been cleared the FDA for use with compatible iPhones1, providing a comprehensive digital offering for its FreeStyle Libre 2 integrated continuous glucose monitoring system. Now cleared in the U.S., Abbott's FreeStyle Libre 2 app helps people manage diabetes from their iPhone. Approved for adults and children 4 and older with diabetes, the new FreeStyle Libre 2 app creates a seamless experience for users and healthcare professionals. The app enables users to get glucose readings directly on their iPhones without the use of a reader.

ShowHide Related Items >><<
ABT Abbott
$121.00 /

-0.11 (-0.09%)

ABT Abbott
$121.00 /

-0.11 (-0.09%)

07/30/21 SVB Leerink
DexCom price target raised to $500 from $485 at SVB Leerink
07/23/21 Raymond James
Abbott price target raised to $128 from $116 at Raymond James
07/12/21 Wells Fargo
Abbott price target raised to $135 from $125 at Wells Fargo
07/01/21 Piper Sandler
DexCom settlement with Abbott could be lucrative, says Piper Sandler
ABT Abbott
$121.00 /

-0.11 (-0.09%)

ABT Abbott
$121.00 /

-0.11 (-0.09%)

ABT Abbott
$121.00 /

-0.11 (-0.09%)

ABT Abbott
$121.00 /

-0.11 (-0.09%)

Hot Stocks
Roche, Carrick Therapeutics collaborate to evaluate samuraciclib combination » 08:38
08/02/21
08/02
08:38
08/02/21
08:38
RHHBY

Roche

$48.26 /

+0.5 (+1.05%)

Carrick Therapeutics…

Carrick Therapeutics announced a clinical collaboration with Roche to evaluate a novel combination of Carrick's samuraciclib and Roche's giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer. The collaboration will utilize Roche's MORPHEUS Phase 1b/2 platform for rapid and efficient combination development, with upfront randomization versus a control group. This new study expands Carrick's portfolio of clinical trials with samuraciclib, which is also being evaluated in a Phase 2a study in combination with fulvestrant for CDK4/6i resistant HR+, HER2- metastatic breast cancer. Other ongoing studies include samuraciclib for the treatment of triple negative breast cancer and prostate cancer - all settings in which CDK7 has been shown to act as a regulator of transcription, the cell cycle and endocrine receptor signalling. Under the agreement, each company is supplying its respective anti-cancer agent to support the trial.

ShowHide Related Items >><<
RHHBY Roche
$48.26 /

+0.5 (+1.05%)

RHHBY Roche
$48.26 /

+0.5 (+1.05%)

07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
07/23/21 Barclays
Roche price target raised to CHF 395 from CHF 375 at Barclays
07/22/21 UBS
Roche price target raised to CHF 375 from CHF 330 at UBS
07/19/21 UBS
Roche price target raised to CHF 345 from CHF 330 at UBS
RHHBY Roche
$48.26 /

+0.5 (+1.05%)

RHHBY Roche
$48.26 /

+0.5 (+1.05%)

RHHBY Roche
$48.26 /

+0.5 (+1.05%)

Hot Stocks
Allogene Therapeutics appoints Barrett, Sato to board of directors » 08:35
08/02/21
08/02
08:35
08/02/21
08:35
ALLO

Allogene Therapeutics

$21.95 /

-0.45 (-2.01%)

, URGN

UroGen Pharma

$15.49 /

+0.02 (+0.13%)

, VRTX

Vertex Pharmaceuticals

$201.55 /

+1.22 (+0.61%)

Allogene Therapeutics…

Allogene Therapeutics (ALLO) announced the appointment of Elizabeth Barrett and Vicki Sato, Ph.D. to the company's Board of Directors. Barrett, an executive with experience in the commercialization of novel oncology therapies, is currently the President and Chief Executive Officer of UroGen Pharma (URGN). Sato served as President of Vertex Pharmaceuticals (VRTX) where she was responsible for research and development, business and corporate management, and commercial, legal and financial operations.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$201.55 /

+1.22 (+0.61%)

URGN UroGen Pharma
$15.49 /

+0.02 (+0.13%)

ALLO Allogene Therapeutics
$21.95 /

-0.45 (-2.01%)

ALLO Allogene Therapeutics
$21.95 /

-0.45 (-2.01%)

06/21/21 Jefferies
Allogene Therapeutics assumed with a Buy at Jefferies
05/20/21 Jefferies
Allogene update exceeds expectation 'on all fronts,' says Jefferies
05/20/21 Stifel
Allogene data 'better than they appear on the surface,' says Stifel
05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
URGN UroGen Pharma
$15.49 /

+0.02 (+0.13%)

04/27/21 H.C. Wainwright
UroGen Pharma price target lowered to $50 from $57 at H.C. Wainwright
11/10/20 Oppenheimer
UroGen Pharma price target lowered to $40 from $48 at Oppenheimer
09/21/20 JPMorgan
UroGen Pharma price target lowered to $26 from $31 at JPMorgan
VRTX Vertex Pharmaceuticals
$201.55 /

+1.22 (+0.61%)

07/30/21 Piper Sandler
Vertex Pharmaceuticals price target raised to $323 from $261 at Piper Sandler
07/20/21 SVB Leerink
Vertex Pharmaceuticals downgraded to Underperform from Market Perform at SVB Leerink
07/19/21 Wolfe Research
Vertex Pharmaceuticals assumed with an Outperform at Wolfe Research
07/01/21 Raymond James
Vertex Pharmaceuticals initiated with a Market Perform at Raymond James
VRTX Vertex Pharmaceuticals
$201.55 /

+1.22 (+0.61%)

URGN UroGen Pharma
$15.49 /

+0.02 (+0.13%)

ALLO Allogene Therapeutics
$21.95 /

-0.45 (-2.01%)

VRTX Vertex Pharmaceuticals
$201.55 /

+1.22 (+0.61%)

VRTX Vertex Pharmaceuticals
$201.55 /

+1.22 (+0.61%)

ALLO Allogene Therapeutics
$21.95 /

-0.45 (-2.01%)

VRTX Vertex Pharmaceuticals
$201.55 /

+1.22 (+0.61%)

Friday
On The Fly
Wall Street in Fives - Must Read Lists at Midday » 12:08
07/30/21
07/30
12:08
07/30/21
12:08
AMZN

Amazon.com

$3,341.78 /

-257.53 (-7.15%)

, PINS

Pinterest

$58.59 /

-13.33 (-18.53%)

, PG

Procter & Gamble

$143.15 /

+3.82 (+2.74%)

, CVX

Chevron

$101.46 /

-1.08 (-1.05%)

, XOM

Exxon Mobil

$57.54 /

-1.37 (-2.33%)

, DUOL

Duolingo

$136.26 /

-0.69 (-0.50%)

, TSLA

Tesla

$691.25 /

+13.9 (+2.05%)

, NVDA

Nvidia

$194.00 /

-2.61 (-1.33%)

, UBER

Uber

$43.97 /

-0.72 (-1.61%)

, BAYRY

Bayer

$15.13 /

+0.24 (+1.61%)

, TEAM

Atlassian

$331.75 /

+64.96 (+24.35%)

, KLAC

KLA Corp.

$342.56 /

+23.295 (+7.30%)

, MAXR

Maxar Technologies

$36.57 /

+1.56 (+4.46%)

, UPWK

Upwork

$49.90 /

-7.56 (-13.16%)

, SAVA

Cassava Sciences

$88.25 /

-15.16 (-14.66%)

, ABBV

AbbVie

$116.80 /

-2.09 (-1.76%)

, GILD

Gilead

$68.54 /

-1.32 (-1.89%)

, TMUS

T-Mobile

$144.78 /

+0.19 (+0.13%)

, ZEN

Zendesk

$129.15 /

-21.57 (-14.31%)

, LBTYA

Liberty Global

$26.76 /

+1 (+3.88%)

, LBTYK

Liberty Global

$26.77 /

+1.085 (+4.22%)

, MDLZ

Mondelez

$63.38 /

+0.05 (+0.08%)

, NOK

Nokia

$6.08 /

+0.035 (+0.58%)

, PFPT

Proofpoint

$174.64 /

+0.015 (+0.01%)

Get caught up quickly on…

ShowHide Related Items >><<
ZEN Zendesk
$129.15 /

-21.57 (-14.31%)

XOM Exxon Mobil
$57.54 /

-1.37 (-2.33%)

UPWK Upwork
$49.90 /

-7.56 (-13.16%)

UBER Uber
$43.97 /

-0.72 (-1.61%)

TSLA Tesla
$691.25 /

+13.9 (+2.05%)

TMUS T-Mobile
$144.78 /

+0.19 (+0.13%)

TEAM Atlassian
$331.75 /

+64.96 (+24.35%)

SAVA Cassava Sciences
$88.25 /

-15.16 (-14.66%)

PINS Pinterest
$58.59 /

-13.33 (-18.53%)

PG Procter & Gamble
$143.15 /

+3.82 (+2.74%)

PFPT Proofpoint
$174.64 /

+0.015 (+0.01%)

NVDA Nvidia
$194.00 /

-2.61 (-1.33%)

NOK Nokia
$6.08 /

+0.035 (+0.58%)

MDLZ Mondelez
$63.38 /

+0.05 (+0.08%)

MAXR Maxar Technologies
$36.57 /

+1.56 (+4.46%)

LBTYA Liberty Global
$26.76 /

+1 (+3.88%)

KLAC KLA Corp.
$342.56 /

+23.295 (+7.30%)

GILD Gilead
$68.54 /

-1.32 (-1.89%)

CVX Chevron
$101.46 /

-1.08 (-1.05%)

BAYRY Bayer
$15.13 /

+0.24 (+1.61%)

AMZN Amazon.com
$3,341.78 /

-257.53 (-7.15%)

ABBV AbbVie
$116.80 /

-2.09 (-1.76%)

AMZN Amazon.com
$3,341.78 /

-257.53 (-7.15%)

07/30/21 JPMorgan
Amazon.com price target lowered to $4,100 from $4,600 at JPMorgan
07/30/21 Cowen
Amazon.com price target lowered to $4400 from $4600 at Cowen
07/30/21 UBS
Amazon.com price target lowered to $4,020 from $4,350 at UBS
07/30/21 Oppenheimer
Amazon.com price target lowered to $4,200 from $4,400 at Oppenheimer
PINS Pinterest
$58.59 /

-13.33 (-18.53%)

07/30/21
Fly Intel: Top five analyst downgrades
07/30/21 MKM Partners
Pinterest price target lowered to $74 from $90 at MKM Partners
07/30/21 Morgan Stanley
Pinterest price target lowered to $77 from $83 at Morgan Stanley
07/30/21 Wedbush
Pinterest price target lowered to $70 from $91 at Wedbush
PG Procter & Gamble
$143.15 /

+3.82 (+2.74%)

06/23/21 UBS
Procter & Gamble initiated with a Neutral at UBS
04/21/21
Fly Intel: Top five analyst downgrades
04/21/21 Roth Capital
PureCycle Technologies initiated with a Buy at Roth Capital
04/21/21 Citi
Procter & Gamble downgraded to Neutral from Buy at Citi
CVX Chevron
$101.46 /

-1.08 (-1.05%)

07/23/21 Piper Sandler
Chevron price target raised to $137 from $126 at Piper Sandler
07/22/21
Fly Intel: Top five analyst downgrades
07/22/21 Redburn
Chevron upgraded to Buy from Neutral at Redburn
07/22/21 HSBC
Chevron downgraded to Hold from Buy at HSBC
XOM Exxon Mobil
$57.54 /

-1.37 (-2.33%)

07/23/21 Piper Sandler
Exxon Mobil price target raised to $69 from $63 at Piper Sandler
07/22/21 HSBC
Exxon Mobil price target lowered to $57 from $65 at HSBC
07/12/21
Fly Intel: Top five analyst initiations
07/12/21 BMO Capital
Exxon Mobil initiated with a Market Perform at BMO Capital
DUOL Duolingo
$136.26 /

-0.69 (-0.50%)

TSLA Tesla
$691.25 /

+13.9 (+2.05%)

07/29/21 DZ Bank
Tesla upgraded to Buy from Sell at DZ Bank
07/28/21 Citi
Tesla price target raised to $209 from $175 at Citi
07/27/21 Needham
Tesla saw improvement on cost structure, valuation still too high, says Needham
07/27/21 Roth Capital
Competitive news flow likely drives Tesla 2H21 volatility, says Roth Capital
NVDA Nvidia
$194.00 /

-2.61 (-1.33%)

07/23/21 Jefferies
Intel price target lowered to $52 from $54 at Jefferies
07/23/21 Argus
Nvidia price target raised to $230 from $175 at Argus
07/22/21 Citi
Nvidia price target raised to $223 from $180 at Citi
07/21/21 Oppenheimer
Nvidia price target lowered to $235 from $925 at Oppenheimer
UBER Uber
$43.97 /

-0.72 (-1.61%)

07/22/21 Stifel
Acquisition of Transplace expands Uber Freight's capabilities, says Stifel
07/21/21 DA Davidson
HyreCar initiated with a Buy at DA Davidson
07/01/21 Cowen
Uber target raised to $80 on rising mobility users at Cowen
07/01/21 Arete
Uber upgraded to Neutral from Sell at Arete
BAYRY Bayer
$15.13 /

+0.24 (+1.61%)

05/19/21 Morgan Stanley
Bayer price target raised to EUR 71 from EUR 70 at Morgan Stanley
05/19/21 JPMorgan
JPMorgan upgrades Bayer to Overweight with earnings at 'turning point'
05/18/21 JPMorgan
Bayer upgraded to Overweight from Neutral at JPMorgan
05/14/21 Berenberg
Bayer price target raised to EUR 74 from EUR 68 at Berenberg
TEAM Atlassian
$331.75 /

+64.96 (+24.35%)

07/30/21 Canaccord
Atlassian price target raised to $325 from $275 at Canaccord
07/30/21 Truist
Atlassian price target raised to $270 from $200 at Truist
07/30/21 Mizuho
Atlassian price target raised to $370 from $310 at Mizuho
07/30/21 Piper Sandler
Atlassian price target raised to $308 from $259 at Piper Sandler
KLAC KLA Corp.
$342.56 /

+23.295 (+7.30%)

07/30/21
Fly Intel: Top five analyst upgrades
07/30/21 Cowen
KLA Corp. price target raised to $355 from $335 at Cowen
07/30/21 Needham
KLA Corp. upgraded to Buy from Hold at Needham
07/30/21 Deutsche Bank
KLA Corp. price target raised to $400 from $375 at Deutsche Bank
MAXR Maxar Technologies
$36.57 /

+1.56 (+4.46%)

07/15/21 Morgan Stanley
Maxar Technologies initiated with an Overweight at Morgan Stanley
07/14/21 Baird
Baird starts Maxar Technologies at Neutral, cautious ahead of Legion launch
07/14/21 Baird
Maxar Technologies initiated with a Neutral at Baird
06/22/21 BofA
BofA starts Maxar Technologies at Neutral, sees runway along with risks
UPWK Upwork
$49.90 /

-7.56 (-13.16%)

07/30/21 MKM Partners
Upwork price target raised to $65 from $58 at MKM Partners
07/01/21 BTIG
Upwork price target raised to $76 from $65 at BTIG
05/05/21 BTIG
Upwork price target lowered to $65 from $75 at BTIG
02/25/21 Citi
Upwork price target raised to $75 from $48 at Citi
SAVA Cassava Sciences
$88.25 /

-15.16 (-14.66%)

07/30/21 B. Riley
Cassava Sciences data represents 'home run scenario,' says B. Riley
07/20/21 H.C. Wainwright
Cassava Sciences price target raised to $124 from $97 at H.C. Wainwright
07/15/21
Fly Intel: Top five analyst downgrades
07/15/21 Cantor Fitzgerald
Cassava Sciences downgraded to Neutral from Overweight at Cantor Fitzgerald
ABBV AbbVie
$116.80 /

-2.09 (-1.76%)

07/26/21 Truist
AbbVie assumed with a Buy at Truist
07/26/21 Truist
AbbVie assumed with a Buy at Truist
07/02/21
Fly Intel: Top five analyst initiations
07/02/21 Daiwa
AbbVie initiated with an Outperform at Daiwa
GILD Gilead
$68.54 /

-1.32 (-1.89%)

07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
06/16/21 Roth Capital
JTX-1811 IND-clearance further validates Jounce platform, says Roth Capital
TMUS T-Mobile
$144.78 /

+0.19 (+0.13%)

07/30/21 Truist
T-Mobile price target raised to $175 from $150 at Truist
07/30/21 RBC Capital
T-Mobile upgraded to Outperform from Sector Perform at RBC Capital
07/30/21 RBC Capital
T-Mobile upgraded to Outperform from Sector Perform at RBC Capital
ZEN Zendesk
$129.15 /

-21.57 (-14.31%)

05/27/21
Fly Intel: Top five analyst upgrades
05/27/21 UBS
Zendesk upgraded to Buy from Neutral at UBS
04/30/21 Piper Sandler
Zendesk price target raised to $186 from $180 at Piper Sandler
04/22/21 Wolfe Research
Zendesk initiated with an Outperform at Wolfe Research
LBTYA Liberty Global
$26.76 /

+1 (+3.88%)

07/29/21 Deutsche Bank
Liberty Global named short-term investment idea at Deutsche Bank
06/23/21 JPMorgan
Liberty Global resumed with an Overweight at JPMorgan
05/07/21 Barclays
Liberty Global price target raised to $35 from $32 at Barclays
05/06/21 Pivotal Research
Liberty Global 'moving in the right direction,' says Pivotal Research
LBTYK Liberty Global
$26.77 /

+1.085 (+4.22%)

09/29/20 Pivotal Research
Liberty Global price target raised to $40 from $30 at Pivotal Research
MDLZ Mondelez
$63.38 /

+0.05 (+0.08%)

07/30/21 Goldman Sachs
Mondelez downgraded to Buy from Conviction Buy at Goldman Sachs
07/19/21 Morgan Stanley
Morgan Stanley equity strategist upgrades Consumer Staples, downgrades Materials
07/19/21 Deutsche Bank
Mondelez price target raised to $71 from $70 at Deutsche Bank
NOK Nokia
$6.08 /

+0.035 (+0.58%)

07/30/21 Cowen
Cowen upgrades Nokia to Outperform on favorable demand, turnaround progress
07/30/21 Cowen
Nokia upgraded to Outperform from Market Perform at Cowen
07/14/21
Fly Intel: Top five analyst upgrades
07/14/21 JPMorgan
JPMorgan upgrades Nokia on 'more room to run' for mobile turnaround
PFPT Proofpoint
$174.64 /

+0.015 (+0.01%)

07/30/21 JMP Securities
Proofpoint downgraded to Market Perform from Outperform at JMP Securities
05/24/21 Baird
Proofpoint downgraded to Neutral from Outperform at Baird
04/27/21 Truist
Proofpoint downgraded to Hold from Buy at Truist
ZEN Zendesk
$129.15 /

-21.57 (-14.31%)

XOM Exxon Mobil
$57.54 /

-1.37 (-2.33%)

UPWK Upwork
$49.90 /

-7.56 (-13.16%)

UBER Uber
$43.97 /

-0.72 (-1.61%)

TSLA Tesla
$691.25 /

+13.9 (+2.05%)

TMUS T-Mobile
$144.78 /

+0.19 (+0.13%)

TEAM Atlassian
$331.75 /

+64.96 (+24.35%)

SAVA Cassava Sciences
$88.25 /

-15.16 (-14.66%)

PINS Pinterest
$58.59 /

-13.33 (-18.53%)

PG Procter & Gamble
$143.15 /

+3.82 (+2.74%)

PFPT Proofpoint
$174.64 /

+0.015 (+0.01%)

NVDA Nvidia
$194.00 /

-2.61 (-1.33%)

NOK Nokia
$6.08 /

+0.035 (+0.58%)

MDLZ Mondelez
$63.38 /

+0.05 (+0.08%)

MAXR Maxar Technologies
$36.57 /

+1.56 (+4.46%)

LBTYA Liberty Global
$26.76 /

+1 (+3.88%)

KLAC KLA Corp.
$342.56 /

+23.295 (+7.30%)

GILD Gilead
$68.54 /

-1.32 (-1.89%)

CVX Chevron
$101.46 /

-1.08 (-1.05%)

BAYRY Bayer
$15.13 /

+0.24 (+1.61%)

AMZN Amazon.com
$3,341.78 /

-257.53 (-7.15%)

ABBV AbbVie
$116.80 /

-2.09 (-1.76%)

  • 29
    Jul
  • 28
    Jul
  • 18
    Mar
  • 08
    Jan
  • 13
    Nov
XOM Exxon Mobil
$57.54 /

-1.37 (-2.33%)

UPWK Upwork
$49.90 /

-7.56 (-13.16%)

UBER Uber
$43.97 /

-0.72 (-1.61%)

TSLA Tesla
$691.25 /

+13.9 (+2.05%)

TMUS T-Mobile
$144.78 /

+0.19 (+0.13%)

SAVA Cassava Sciences
$88.25 /

-15.16 (-14.66%)

PINS Pinterest
$58.59 /

-13.33 (-18.53%)

PG Procter & Gamble
$143.15 /

+3.82 (+2.74%)

PFPT Proofpoint
$174.64 /

+0.015 (+0.01%)

NVDA Nvidia
$194.00 /

-2.61 (-1.33%)

NOK Nokia
$6.08 /

+0.035 (+0.58%)

MDLZ Mondelez
$63.38 /

+0.05 (+0.08%)

MAXR Maxar Technologies
$36.57 /

+1.56 (+4.46%)

GILD Gilead
$68.54 /

-1.32 (-1.89%)

DUOL Duolingo
$136.26 /

-0.69 (-0.50%)

CVX Chevron
$101.46 /

-1.08 (-1.05%)

BAYRY Bayer
$15.13 /

+0.24 (+1.61%)

AMZN Amazon.com
$3,341.78 /

-257.53 (-7.15%)

ABBV AbbVie
$116.80 /

-2.09 (-1.76%)

ZEN Zendesk
$129.15 /

-21.57 (-14.31%)

XOM Exxon Mobil
$57.54 /

-1.37 (-2.33%)

UPWK Upwork
$49.90 /

-7.56 (-13.16%)

UBER Uber
$43.97 /

-0.72 (-1.61%)

TSLA Tesla
$691.25 /

+13.9 (+2.05%)

TMUS T-Mobile
$144.78 /

+0.19 (+0.13%)

TEAM Atlassian
$331.75 /

+64.96 (+24.35%)

SAVA Cassava Sciences
$88.25 /

-15.16 (-14.66%)

PINS Pinterest
$58.59 /

-13.33 (-18.53%)

PG Procter & Gamble
$143.15 /

+3.82 (+2.74%)

PFPT Proofpoint
$174.64 /

+0.015 (+0.01%)

NVDA Nvidia
$194.00 /

-2.61 (-1.33%)

NOK Nokia
$6.08 /

+0.035 (+0.58%)

MDLZ Mondelez
$63.38 /

+0.05 (+0.08%)

MAXR Maxar Technologies
$36.57 /

+1.56 (+4.46%)

KLAC KLA Corp.
$342.56 /

+23.295 (+7.30%)

GILD Gilead
$68.54 /

-1.32 (-1.89%)

DUOL Duolingo
$136.26 /

-0.69 (-0.50%)

CVX Chevron
$101.46 /

-1.08 (-1.05%)

AMZN Amazon.com
$3,341.78 /

-257.53 (-7.15%)

ABBV AbbVie
$116.80 /

-2.09 (-1.76%)

XOM Exxon Mobil
$57.54 /

-1.37 (-2.33%)

UPWK Upwork
$49.90 /

-7.56 (-13.16%)

UBER Uber
$43.97 /

-0.72 (-1.61%)

TSLA Tesla
$691.25 /

+13.9 (+2.05%)

TMUS T-Mobile
$144.78 /

+0.19 (+0.13%)

TEAM Atlassian
$331.75 /

+64.96 (+24.35%)

SAVA Cassava Sciences
$88.25 /

-15.16 (-14.66%)

PINS Pinterest
$58.59 /

-13.33 (-18.53%)

PG Procter & Gamble
$143.15 /

+3.82 (+2.74%)

NVDA Nvidia
$194.00 /

-2.61 (-1.33%)

NOK Nokia
$6.08 /

+0.035 (+0.58%)

MDLZ Mondelez
$63.38 /

+0.05 (+0.08%)

MAXR Maxar Technologies
$36.57 /

+1.56 (+4.46%)

KLAC KLA Corp.
$342.56 /

+23.295 (+7.30%)

GILD Gilead
$68.54 /

-1.32 (-1.89%)

CVX Chevron
$101.46 /

-1.08 (-1.05%)

AMZN Amazon.com
$3,341.78 /

-257.53 (-7.15%)

ABBV AbbVie
$116.80 /

-2.09 (-1.76%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.